Universal Beteiligungs und Servicegesellschaft mbH Buys New Stake in Hinge Health Inc. $HNGE

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Hinge Health Inc. (NYSE:HNGE) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 18,671 shares of the company’s stock, valued at approximately $966,000.

A number of other large investors have also made changes to their positions in the business. Lisanti Capital Growth LLC acquired a new stake in shares of Hinge Health in the 2nd quarter worth $3,089,000. CHURCHILL MANAGEMENT Corp purchased a new stake in Hinge Health in the second quarter valued at about $828,000. Strategic Blueprint LLC purchased a new stake in Hinge Health in the second quarter valued at about $346,000. FNY Investment Advisers LLC acquired a new stake in Hinge Health in the second quarter worth about $310,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Hinge Health during the second quarter worth about $114,000.

Hinge Health Stock Performance

Shares of NYSE:HNGE opened at $50.12 on Thursday. Hinge Health Inc. has a twelve month low of $33.42 and a twelve month high of $62.18. The stock has a 50 day simple moving average of $49.13.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.18. The business had revenue of $154.21 million for the quarter, compared to analyst estimates of $142.44 million. The business’s revenue for the quarter was up 53.3% on a year-over-year basis. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hinge Health announced that its board has approved a stock repurchase program on Wednesday, November 12th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 7.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

HNGE has been the topic of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Hinge Health from $61.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Piper Sandler reissued an “overweight” rating and set a $71.00 target price (up previously from $70.00) on shares of Hinge Health in a research report on Wednesday, November 5th. Stifel Nicolaus upped their price target on shares of Hinge Health from $63.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. JMP Securities lifted their price objective on shares of Hinge Health from $58.00 to $65.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Evercore ISI boosted their price objective on shares of Hinge Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hinge Health currently has an average rating of “Moderate Buy” and an average target price of $59.93.

Insider Buying and Selling at Hinge Health

In other news, major shareholder Bessemer Venture Partners X. L. sold 725,000 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $40.05, for a total value of $29,036,250.00. Following the completion of the transaction, the insider owned 3,383,707 shares of the company’s stock, valued at $135,517,465.35. The trade was a 17.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James Budge sold 44,589 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $47.47, for a total value of $2,116,639.83. Following the completion of the sale, the chief financial officer owned 479,878 shares in the company, valued at $22,779,808.66. The trade was a 8.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 791,839 shares of company stock valued at $32,148,273 in the last three months.

Hinge Health Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.